GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (TSXV:RX) » Definitions » Gross-Profit-to-Asset %

Biosyent (TSXV:RX) Gross-Profit-to-Asset % : 68.88% (As of Sep. 2024)


View and export this data going back to 1979. Start your Free Trial

What is Biosyent Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Biosyent's annualized Gross Profit for the quarter that ended in Sep. 2024 was C$29.94 Mil. Biosyent's average Total Assets over the quarter that ended in Sep. 2024 was C$43.47 Mil. Therefore, Biosyent's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 was 68.88%.


Biosyent Gross-Profit-to-Asset % Historical Data

The historical data trend for Biosyent's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent Gross-Profit-to-Asset % Chart

Biosyent Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 53.56 54.00 64.01 58.87 62.42

Biosyent Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 69.83 64.68 60.29 69.43 68.88

Competitive Comparison of Biosyent's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biosyent's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biosyent's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Biosyent's Gross-Profit-to-Asset % falls into.



Biosyent Gross-Profit-to-Asset % Calculation

Biosyent's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=25.598/( (40.485+41.529)/ 2 )
=25.598/41.007
=62.42 %

Biosyent's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=29.944/( (41.478+45.471)/ 2 )
=29.944/43.4745
=68.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Sep. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Biosyent Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Biosyent's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosyent Business Description

Traded in Other Exchanges
Address
2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.m.
Executives
Fax Investments Inc. 10% Security Holder
Peter Douglas Lockhard Director
Seyed Ahmad Ashrafi Director
Sharan Raghubir Senior Officer
Rene Goehrum 10% Security Holder, Director, Senior Officer
Biosyent Inc. Issuer
Fax Capital Corp. 10% Security Holder
Joost Van Der Mark Senior Officer
Robert Joseph March Senior Officer
Sara Elford Director
Alfred D'souza Director

Biosyent Headlines

No Headlines